Literature DB >> 18551223

[Immunotherapies for drug addictions].

Ivan Montoya.   

Abstract

Immunotherapies in the form of vaccines (active immunization) or monoclonal antibodies (passive immunization) appear safe and a promising treatment approaches for some substance-related disorders. The mechanism of action of the antibody therapy is by preventing the rapid entry of drugs of abuse into the central nervous system. In theory, immunotherapies could have several clinical applications. Monoclonal antibodies may be useful to treat drug overdoses and prevent the neurotoxic effects of drugs by blocking the access of drugs to the brain. Vaccines may help to prevent the development of addiction, initiate drug abstinence in those already addicted to drugs, or prevent drug use relapse by reducing the pharmacological effects and rewarding properties of the drugs of abuse on the brain. Passive immunization with monoclonal antibodies has been investigated for cocaine, methamphetamine, nicotine, and phencyclidine (PCP). Active immunization with vaccines has been studied for cocaine, heroin, methamphetamine, and nicotine. These immunotherapies seem promising therapeutic tools and are at different stages in their development before they can be approved by regulatory agencies for the treatment of substance-related disorders. The purpose of this article is to review the current immunotherapy approaches with emphasis on the risks and benefits for the treatment of these disorders.

Entities:  

Mesh:

Year:  2008        PMID: 18551223      PMCID: PMC2633931     

Source DB:  PubMed          Journal:  Adicciones        ISSN: 0214-4840            Impact factor:   2.979


  14 in total

Review 1.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.

Authors:  A T McLellan; D C Lewis; C P O'Brien; H D Kleber
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

2.  Future of anti-addiction vaccines.

Authors:  Thomas R Kosten
Journal:  Stud Health Technol Inform       Date:  2005

3.  Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.

Authors:  Dorothy K Hatsukami; Stephen Rennard; Douglas Jorenby; Michael Fiore; Joseph Koopmeiners; Arjen de Vos; Gary Horwith; Paul R Pentel
Journal:  Clin Pharmacol Ther       Date:  2005-11       Impact factor: 6.875

4.  Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats.

Authors:  Mark G LeSage; Daniel E Keyler; Yoko Hieda; Greg Collins; Danielle Burroughs; Chap Le; Paul R Pentel
Journal:  Psychopharmacology (Berl)       Date:  2005-07-01       Impact factor: 4.530

Review 5.  The future of vaccines in the management of addictive disorders.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Tracie Gardner; Thomas R Kosten
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

Review 6.  The blood-brain interface.

Authors:  M W Bradbury; S L Lightman
Journal:  Eye (Lond)       Date:  1990       Impact factor: 3.775

7.  Changes in heroin self-administration by a rhesus monkey after morphine immunisation.

Authors:  K F Bonese; B H Wainer; F W Fitch; R M Rothberg; C R Schuster
Journal:  Nature       Date:  1974-12-20       Impact factor: 49.962

Review 8.  Dopamine in drug abuse and addiction: results of imaging studies and treatment implications.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; James M Swanson; Frank Telang
Journal:  Arch Neurol       Date:  2007-11

9.  A vaccine for nicotine dependence: targeting the drug rather than the brain.

Authors:  Paul Pentel; David Malin
Journal:  Respiration       Date:  2002       Impact factor: 3.580

Review 10.  Biotechnology and the treatment of addictive disorders: new opportunities.

Authors:  Ahmed Elkashef; Jamie Biswas; Jane B Acri; Frank Vocci
Journal:  BioDrugs       Date:  2007       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.